A Phase 1b, Randomized, Double-blind, Sponsor-Unblinded, Placebo-Controlled 4-Way Crossover Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 in Participants With Narcolepsy Type 1
Latest Information Update: 20 Sep 2025
At a glance
- Drugs DSP 0187 (Primary)
- Indications Narcolepsy
- Focus Therapeutic Use
- Sponsors Jazz Pharmaceuticals Inc
Most Recent Events
- 16 May 2025 Status changed from not yet recruiting to recruiting.
- 13 May 2025 New trial record